Skip to main content
Guttmacher Institute

Search

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
Guttmacher Institute
Donate

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact
Policy Analysis
September 2010

The Impact of Medication Abortion <br />10 Years After FDA Approval

Reproductive rights are under attack. Will you help us fight back with facts?

Donate

On September 28, 2000, the U.S. Food and Drug Administration (FDA) approved the use of the abortion drug mifepristone (in combination with a second drug, misoprostol) as an alternative to surgical abortion for terminating early pregnancies. In the decade since, use of early medication abortion has expanded substantially, with growing numbers of providers offering the service, and its approval has given many women a choice between medication or a surgical procedure when seeking an early abortion.

Both the number of medication abortions and the number of providers offering them increased dramatically between 2000 and 2007, even as the total number of abortions performed in the United States declined. In 2007, 158,000 medication abortions were performed using mifepristone, accounting for an estimated 21% of all eligible abortions (those performed prior to nine weeks’ gestation) that year. Preliminary figures suggest use of mifepristone has continued to grow 10–15% annually since 2007.

Although the introduction of mifepristone did not increase the overall incidence of abortion, it does appear to have contributed to a change in the timing of women’s abortions. A larger proportion of abortions take place at earlier gestations than they did before the drug was introduced. The Centers for Disease Control and Prevention report that although the proportion of women obtaining abortions in the first trimester has remained stable, the proportion of abortions obtained at nine weeks’ gestation or earlier has increased, as has the proportion obtained within six weeks’ gestation.

Prior to FDA approval, medication abortion was described as having the potential to change the nature of abortion provision in the United States. Abortion was expected to become more broadly available, particularly in rural areas without a surgical abortion provider. However, Guttmacher research published last year found that while use of mifepristone has become widespread—and has contributed to the shift toward earlier abortions—it has not substantially improved women’s geographic access to abortion services. Most medication abortions are provided at or near facilities that already offered surgical abortions.

Click here for more information:

Facts on Induced Abortion in the United States

The incidence of abortion in the United States

The effect of mifepristone on abortion access

First published online: September 27, 2010

Share

Printer-friendly version

US Policy Resources

More
Guttmacher Institute

Center facts. Shape policy.
Advance sexual and reproductive rights.

Donate Now
Newsletter Signup  Contact Us 
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Footer

  • Privacy Policy
  • Accessibility Statement
© 2025 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.